{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer%2C+Metastatic&page=4",
    "query": {
      "condition": "Pancreatic Cancer, Metastatic",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 911,
    "total_pages": 92,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer%2C+Metastatic&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer%2C+Metastatic&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T09:11:36.219Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05642962",
      "title": "Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Ductal Adenocarcinoma",
        "Metastatic Pancreatic Cancer",
        "Metastatic Pancreatic Adenocarcinoma",
        "Metastatic Pancreatic Carcinoma",
        "Pancreatic Carcinoma",
        "Pancreatic Carcinoma Metastatic",
        "Pancreatic Carcinoma Non-resectable",
        "Pancreatic Cancer",
        "Pancreatic Cancer Non-resectable",
        "Pancreatic Cancer Stage IV",
        "Pancreatic Cancer Metastatic",
        "PDAC",
        "PDAC - Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Pertzye",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2022-11-30",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-10-08T09:11:36.219Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05642962"
    },
    {
      "nct_id": "NCT00005869",
      "title": "Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "rubitecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-08T09:11:36.219Z",
      "location_count": 1,
      "location_summary": "Dublin, California",
      "locations": [
        {
          "city": "Dublin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005869"
    },
    {
      "nct_id": "NCT03375320",
      "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Functioning Pancreatic Neuroendocrine Tumor",
        "Intermediate Grade Lung Neuroendocrine Neoplasm",
        "Locally Advanced Digestive System Neuroendocrine Neoplasm",
        "Locally Advanced Digestive System Neuroendocrine Tumor G1",
        "Locally Advanced Lung Neuroendocrine Neoplasm",
        "Locally Advanced Pancreatic Neuroendocrine Tumor",
        "Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm",
        "Low Grade Lung Neuroendocrine Neoplasm",
        "Lung Neuroendocrine Tumor",
        "Lung Neuroendocrine Tumor G2",
        "Metastatic Digestive System Neuroendocrine Neoplasm",
        "Metastatic Digestive System Neuroendocrine Tumor G1",
        "Metastatic Lung Neuroendocrine Neoplasm",
        "Metastatic Lung Neuroendocrine Tumor",
        "Metastatic Pancreatic Neuroendocrine Neoplasm",
        "Metastatic Pancreatic Neuroendocrine Tumor",
        "Metastatic Thymus Neuroendocrine Neoplasm",
        "Neuroendocrine Neoplasm",
        "Neuroendocrine Tumor",
        "Neuroendocrine Tumor G2",
        "Non-Functioning Pancreatic Neuroendocrine Tumor",
        "Pancreatic Serotonin-Producing Neuroendocrine Tumor",
        "Thymus Neuroendocrine Tumor",
        "Unresectable Digestive System Neuroendocrine Neoplasm",
        "Unresectable Digestive System Neuroendocrine Tumor G1",
        "Unresectable Lung Neuroendocrine Neoplasm",
        "Unresectable Pancreatic Neuroendocrine Neoplasm",
        "Unresectable Thymus Neuroendocrine Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 298,
      "start_date": "2018-10-26",
      "completion_date": "2027-09-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-08T09:11:36.219Z",
      "location_count": 432,
      "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03375320"
    },
    {
      "nct_id": "NCT03127124",
      "title": "QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma Metastatic"
      ],
      "interventions": [
        {
          "name": "NANT-008",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil Injectable Product",
          "type": "DRUG"
        },
        {
          "name": "Avastin Injectable Product",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium Injection",
          "type": "DRUG"
        },
        {
          "name": "Eloxatin Injectable Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NantPharma, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-02-27",
      "completion_date": "2023-12-06",
      "has_results": false,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-10-08T09:11:36.219Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03127124"
    },
    {
      "nct_id": "NCT00805688",
      "title": "Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Blood Draws",
          "type": "PROCEDURE"
        },
        {
          "name": "Pedometer",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2008-11-12",
      "completion_date": "2018-02-27",
      "has_results": false,
      "last_update_posted_date": "2018-03-06",
      "last_synced_at": "2026-10-08T09:11:36.219Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00805688"
    },
    {
      "nct_id": "NCT04132505",
      "title": "Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Pancreatic Adenocarcinoma",
        "Stage IV Pancreatic Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2019-10-22",
      "completion_date": "2026-03-24",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-08T09:11:36.219Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04132505"
    },
    {
      "nct_id": "NCT00003427",
      "title": "Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anal Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer",
        "Gastric Cancer",
        "Gastrointestinal Carcinoid Tumor",
        "Liver Cancer",
        "Pancreatic Cancer",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "1998-04",
      "completion_date": "2002-04",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-10-08T09:11:36.219Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003427"
    },
    {
      "nct_id": "NCT04659603",
      "title": "Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer Metastatic",
        "Pancreatic Carcinoma Metastatic"
      ],
      "interventions": [
        {
          "name": "tusamitamab ravtansine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-03-29",
      "completion_date": "2025-01-19",
      "has_results": true,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-10-08T09:11:36.219Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Boston, Massachusetts • Madison, Wisconsin",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04659603"
    },
    {
      "nct_id": "NCT05712889",
      "title": "Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "VIP236 (Q3W)",
          "type": "DRUG"
        },
        {
          "name": "VIP236 (Q2W)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vincerx Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2023-01-24",
      "completion_date": "2024-10-10",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-10-08T09:11:36.219Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Austin, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05712889"
    },
    {
      "nct_id": "NCT03269526",
      "title": "BATs Treatment for Pancreatic Cancer, Phase Ib/II",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Pancreatic Adenocarcinoma",
        "Metastatic Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "EGFR BATs after standard of care chemo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-07-28",
      "completion_date": "2026-04-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-10-08T09:11:36.219Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03269526"
    }
  ]
}